Wednesday, December 16, 2015

Prostate Cancer Drug Treatment Leads to Alzheimers!

ADT (androgen deprivation therapy) is a relatively new drug therapy for prostate cancer that cuts off the bodies ability to make testosterone.
We at the PAF have been suspicious of this chemical castration therapy since it became a common protocol in the mid 1990's.
ADT side effects are regularly reported by members of the PAF and include hot flashes, calcium deficiency, fatigue, loss of libido and memory impairment.
Now a new study published in the Journal of Clinical Urology this December ties ADT to a higher incidence of Alzheimer's disease.
This study of 2400 men for two decades by the University of Pennsylvania and Stanford University surprised the researchers.
Men on ADT in the study had an 88% higher risk of getting Alzheimers. In fact those men on testosterone blockade for over 1 year increased their Alzheimers Risk by more than double those men who did not use this protocol.
We feel that the risk of debilitating Alzheimers outweigh the benefits of ADT
What do you think?
We suggest asking your oncologist his position on this provocative study.
ADT has become the treatment path of choice for men with advanced prostate cancer!